Robert Driscoll
Stock Analyst at Wedbush
(4.45)
# 1,136
Out of 4,564 analysts
353
Total ratings
46.2%
Success rate
10.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintained: Buy | $41 | $30.83 | +33.01% | 24 | Jul 23, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $165 → $192 | $190.90 | +0.63% | 24 | Jul 23, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $10 | $5.12 | +95.31% | 15 | Jul 20, 2026 | |
| REPL Replimune Group | Reiterated: Hold | $6 → $9 | $10.82 | -16.82% | 18 | Jun 30, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $53 | $30.34 | +74.69% | 15 | Jun 16, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $36 | $10.51 | +242.53% | 30 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $58 | $35.44 | +63.66% | 25 | Jun 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $37 | $17.48 | +111.67% | 18 | Jun 11, 2026 | |
| CTMX CytomX Therapeutics | Reiterated: Buy | $11 | $3.33 | +230.33% | 18 | Jun 4, 2026 | |
| CBIO Crescent Biopharma | Maintained: Buy | $27 | $16.45 | +64.13% | 5 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $1.83 | +665.03% | 14 | Jun 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $30 | $9.32 | +221.89% | 6 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $2.68 | +123.88% | 2 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $72.08 | +10.99% | 4 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $34 | $18.08 | +88.05% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $8.30 | +201.20% | 10 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $0.65 | +823.08% | 8 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $33 | $27.76 | +18.88% | 11 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $8.30 | +32.53% | 26 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $7 → $5 | $9.40 | -46.81% | 3 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $15.68 | +129.59% | 12 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $23.61 | +56.71% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $6 → $1 | $0.36 | +177.78% | 4 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $4.61 | -13.23% | 13 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $5.95 | n/a | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $1.43 | n/a | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.08 | n/a | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $130.43 | n/a | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $6 | $4.38 | n/a | 8 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $13.86 | n/a | 4 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $7 → $10 | $0.0001 | n/a | 2 | Mar 19, 2020 |
Arcus Biosciences
Jul 23, 2026
Maintained: Buy
Price Target: $41
Current: $30.83
Upside: +33.01%
Revolution Medicines
Jul 23, 2026
Reiterated: Buy
Price Target: $165 → $192
Current: $190.90
Upside: +0.63%
Foghorn Therapeutics
Jul 20, 2026
Maintained: Buy
Price Target: $10
Current: $5.12
Upside: +95.31%
Replimune Group
Jun 30, 2026
Reiterated: Hold
Price Target: $6 → $9
Current: $10.82
Upside: -16.82%
Tyra Biosciences
Jun 16, 2026
Reiterated: Buy
Price Target: $53
Current: $30.34
Upside: +74.69%
Kura Oncology
Jun 15, 2026
Reiterated: Buy
Price Target: $36
Current: $10.51
Upside: +242.53%
IDEAYA Biosciences
Jun 12, 2026
Reiterated: Buy
Price Target: $58
Current: $35.44
Upside: +63.66%
Cullinan Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: $37
Current: $17.48
Upside: +111.67%
CytomX Therapeutics
Jun 4, 2026
Reiterated: Buy
Price Target: $11
Current: $3.33
Upside: +230.33%
Crescent Biopharma
Jun 1, 2026
Maintained: Buy
Price Target: $27
Current: $16.45
Upside: +64.13%
Jun 1, 2026
Maintained: Buy
Price Target: $14
Current: $1.83
Upside: +665.03%
May 27, 2026
Reiterated: Buy
Price Target: $38 → $30
Current: $9.32
Upside: +221.89%
May 18, 2026
Reiterated: Buy
Price Target: $6
Current: $2.68
Upside: +123.88%
May 18, 2026
Reiterated: Buy
Price Target: $80
Current: $72.08
Upside: +10.99%
May 14, 2026
Reiterated: Buy
Price Target: $29 → $34
Current: $18.08
Upside: +88.05%
May 14, 2026
Reiterated: Buy
Price Target: $25
Current: $8.30
Upside: +201.20%
May 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $0.65
Upside: +823.08%
May 14, 2026
Reiterated: Buy
Price Target: $19 → $33
Current: $27.76
Upside: +18.88%
May 13, 2026
Maintained: Hold
Price Target: $11
Current: $8.30
Upside: +32.53%
May 12, 2026
Maintained: Sell
Price Target: $7 → $5
Current: $9.40
Upside: -46.81%
May 8, 2026
Reiterated: Buy
Price Target: $45 → $36
Current: $15.68
Upside: +129.59%
May 8, 2026
Maintained: Buy
Price Target: $37
Current: $23.61
Upside: +56.71%
Dec 19, 2025
Downgraded: Hold
Price Target: $6 → $1
Current: $0.36
Upside: +177.78%
Aug 7, 2025
Maintained: Hold
Price Target: $4
Current: $4.61
Upside: -13.23%
Jul 14, 2025
Initiated Coverage: Buy
Price Target: $27
Current: $5.95
Upside: n/a
May 8, 2025
Maintained: Buy
Price Target: $7 → $6
Current: $1.43
Upside: n/a
Aug 14, 2024
Reiterated: Buy
Price Target: $8
Current: $2.08
Upside: n/a
Nov 19, 2021
Maintained: Buy
Price Target: $67
Current: $130.43
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $7 → $6
Current: $4.38
Upside: n/a
Oct 5, 2020
Maintained: Buy
Price Target: $8
Current: $13.86
Upside: n/a
Mar 19, 2020
Downgraded: Hold
Price Target: $7 → $10
Current: $0.0001
Upside: n/a